Journey Medical Corporation Stock Analysis & AI Score
Journey Medical Corporation (DERM) has an ST Score of 40.6 (C), driven by its Forecast (A-) and held back by its Sentiment (F). Analysts rate it Buy with a $11.75 price target (+85.9% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Journey Medical Corporation (DERM) has an ST Score of 40.6 (C), driven by its Forecast (A-) and held back by its Sentiment (F). Analysts rate it Buy with a $11.75 price target (+85.9% upside).
- Strongest
- ForecastA-
- Weakest
- SentimentF
All factor grades
- ForecastA-
- ValuationB
- GrowthB
- ProfitabilityC
- Financial StrengthD
- MomentumD
- SentimentF
- Piotroski4/9
Contact
DERM stock: frequently asked questions
What is DERM's ST Score?
Journey Medical Corporation (DERM) has an ST Score of 40.6 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is DERM a buy, hold, or sell?
Analysts rate DERM a Buy, with a price target of $11.75 (+85.9% vs the current price). Our ST Score grades it C (40.6/100). The ST Score is a data-driven signal, not a recommendation.
What are DERM's factor grades?
Valuation B, Profitability C, Financial Strength D, Momentum D, Growth B, Forecast A-, Sentiment F.
What is DERM's valuation grade?
Journey Medical Corporation (DERM) earns a valuation grade of B, measured against Drug Manufacturers - Specialty & Generic peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is DERM's growth grade?
Journey Medical Corporation (DERM) earns a growth grade of B, measured against Drug Manufacturers - Specialty & Generic peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is DERM's profitability grade?
Journey Medical Corporation (DERM) earns a profitability grade of C, measured against Drug Manufacturers - Specialty & Generic peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is DERM's financial strength grade?
Journey Medical Corporation (DERM) earns a financial strength grade of D, measured against Drug Manufacturers - Specialty & Generic peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for DERM?
The average analyst price target for Journey Medical Corporation (DERM) is $11.75 from 3 analysts, which is +85.9% versus the recent price of $6.32.
What is DERM's Piotroski score?
Journey Medical Corporation (DERM) has a Piotroski F-Score of 4 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.